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Abstract
BACKGROUND/AIMS: The GNAS1 locus encodes the
GAs protein, which stimulates the formation of cyclo-
adenosinemonophosphate (cAMP). The cAMP pathway
mediates pleiotropic effects, including the regulation
of apoptosis and proliferation. We have recently
shown that TT genotypes of the single-nucleotide poly-
morphism T393C in the gene GNAS1 predict the clini-
cal outcome of patients with various carcinomas.
METHODS: Eighty-seven patients with intrahepatic
cholangiocarcinoma (ICC) were retrospectively geno-
typed to elucidate a potential association between
T393C genotypes and clinical outcome. RESULTS:
ICCs of patients with homozygous TT genotypes re-
vealed a higher proliferation rate and a lower apoptotic
rate. Homozygous TT patients were at highest risk for
cancer-related deaths (hazard ratio = 2.74; 95% con-
fidence interval = 1.03–7.28) compared with C-allele
carriers. Kaplan-Meier curves for disease-specific over-
all and local recurrence-free survival in a subgroup
with R0-resected ICC showed a significant associa-
tion of T393 homozygosity with outcome, which was
confirmed in multivariate Cox regression analysis.
CONCLUSIONS: GNAS1 T393C is a novel independent
host factor for disease progression in patients with
ICC. Our finding that TT homozygosity (and not CC
homozygosity) was associated with unfavorable clini-
cal outcome points to the complex and differing func-
tional effects induced by GNAS1 T393C polymorphism
in various human carcinomas.
Neoplasia (2007) 9, 159–165
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Introduction
Cholangiocarcinoma (CCC) is composed of cells re-
sembling those of bile ducts. CCC arises either from the
extrahepatic duct, including the hilar bifurcation, or from
intrahepatic ducts. Intrahepatic cholangiocarcinoma (ICC)
occurs less frequently than extrahepatic bile duct carcinoma,
but ranks second to hepatocellular carcinoma among primary
malignant liver tumors. In western countries, ICC accounts for
about 10% of primary liver malignancies, with increasing inci-
dence in the last two decades [1,2]. Our group recently showed
that R0 resection can provide prolonged survival, even in
patients with advance ICC [3]. Poor results after R1 resection
and high operative morbidity and mortality do not justify pallia-
tive resections but underline the need for an improved pre-
operative assessment of resectability to avoid unnecessary
surgical therapy. The identification of patients with high-risk
ICC may thus be helpful for optimizing decision making for
surgical treatment. Therefore, it is desirable to identify molec-
ular markers that individually predict tumor behavior and may
facilitate individualized therapy even before initial surgery.
The most common genetic alterations in ICC are mutations of
RAS and TP53 genes. However, besides a broad range in the
geographic incidences of k-RAS mutations in ICC (from 4%
among Thai patients [4] to 100% among British patients [5]),
the application of thesemarkers requires tumor tissue, whereas
an ideal prognostic factor is based on tissue material ac-
quired before surgery. Such factors might be preoperatively
determined tumor-related cell-free nucleic acids in plasma and
serum. Recently, the preoperative plasma transcript AA454543
level has been identified as a prognostic parameter in hepato-
cellular carcinoma [6,7]. However, such novel and promising
prognostic markers are still based on the presence of tumor
mass. A genetic host factor may offer a better stratification of
patients into more refined risk categories without the need for
tumor tissue. Necessary genetic information might be derived
from a blood sample even years before cancer develops.
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We have recently shown that T393C polymorphism in the
gene GNAS1, which encodes the Gas subunit of heterotri-
meric G protein, is significantly associated with the clinical
outcome of patients suffering from bladder cancer [8], colo-
rectal cancer [9], chronic lymphocytic leukemia [10], and
renal cell carcinoma [11]. We previously demonstrated that
the T allele of GNAS1 T393C polymorphism is associated
with increased Gas mRNA expression in a variety of tissues,
including tumor tissue [8], and might induce a change in the
mRNA folding structures predicted by MFOLD [9,12].
MFOLD is a set of programs developed by Zuker that uses
dynamic computer programming to predict RNA secondary
structures. In vitro experiments suggest that an increased
expression of Gas is associated with enhanced apoptosis
and that the second messenger, cycloadenosinemonophos-
phate (cAMP), which functions downstream of G proteins,
plays a major role in this proapoptotic process [13–17].
The aim of the present study was, thus, to investigate a
potential association between genotypes of T393C poly-
morphism and disease progression in patients with ICC.
Moreover, we investigated a possible genotype-dependent
correlation with tumor cell proliferation (using Ki67 immuno-
histochemistry) and apoptosis [applying the terminal deoxy-




This study comprises a total of 87 consecutive ICC
patients (with a mean age of 59 ± 11.2 years) seen at the
Clinic of General Surgery and Transplantation of the Univer-
sity Hospital Essen (Essen, Germany) between August 1998
and June 2004 who underwent surgical exploration for in-
tended liver resection. In 47 patients (54%), liver resection
was performed. The diagnosis of ICCwas based on histology
obtained by preoperative or intraoperative biopsy or by ex-
amination of resected liver specimens. Patients with hilar
CCC, gallbladder carcinoma, or mixed hepatocellular carci-
noma/CCC and cirrhosis were excluded from this study.
Among the resection group, one patient suffered from pri-
mary sclerosing cholangitis without cirrhosis; hepatolithiasis
was not present in any case. Tumors were classified accord-
ing to the pTNM system (sixth edition [18]). Detailed clinical
data, including preoperative therapy, operative details, and
pathological findings such as surgical radicability, tumor
staging, and clinical follow-up, were available. Data were
completed by January 2005, with a minimum follow-up
period of 6 months or until death. The mean follow-up was
13.8months, and themaximum follow-upwas 73months. For
statistical analysis, two groups were created: (1) the explo-
ration group consisting of ICC with no further surgical re-
section after explorative laparotomy, and (2) the resection
group consisting of all cases with liver resection with detailed
clinicopathological data. Twenty-three of 28 deaths of pa-
tients with resected ICC were strictly cancer-related (recur-
rence). One patient died of cerebral infarction, one died of
respiratory insufficiency, and two died of multiorgan failure.
Regarding the exploration group, no data on the exact cause
of death were available. All patients of this subgroup died
within a short time (mean survival time, 8 months) due to
advance-stage cancer.
Blood Donors
The Caucasian control sample consisted of 163 age-
matched and sex-matched healthy white Caucasian indi-
viduals of either gender who were recruited at the local
Department for Transfusion Medicine, University Hospital
Essen. All samples were collected at random from subjects
donating blood; the details of this sample have been pub-
lished previously [19]. The control sample consisted of
69 males and 94 females, and the mean age was 58.5 ±
4.2 years. Healthy blood donors gave written consent for the
inclusion of their blood in this study.
The present study was strictly performed according to
the Declaration of Helsinki. The study was approved by the
Ethics Committee of the University Hospital of Essen.
Genotyping
For the genotyping of T393C polymorphism, genomic DNA
was isolated from several 10- to 20-mm-thick sections from
routinely processed paraffin blocks (tumor tissue and normal
tissue or partly exclusive non-neoplastic tissue in the explora-
tion group) and placed in a 1.5-ml microfuge tube. The sam-
ples were dewaxed on a shaker incubator at 45jC for
5 minutes. After centrifugation at room temperature, the su-
pernatant was removed. Pellets were washed in 1000 ml of
ethanol and again centrifuged at full speed for 5 minutes. The
supernatant was removed, and the open microfuge tube was
incubated at 45jC for 2 to 5 minutes until the ethanol had
evaporated. DNA was purified with the QIAamp DNA Mini Kit
(Qiagen, Hilden, Germany). Tissue pellets were resuspended
in 180 ml of buffer ATL/20 ml of proteinase K and incubated
overnight on a shaker incubator at 56jC. Further processing
of the samples was performed according to the recommen-
dations of the supplier. Genotypes for T393C polymorphism
were determined as previously described [8].
Ki67 Immunostaining and TUNEL
Ki67 immunohistochemistry was performed on 5-mm-thick
paraffin sections. Dewaxed and rehydrated sections were
incubated with hydrogen peroxide to block endogenous
peroxidase. Immunostaining of Ki67 was carried out with an
automated staining device (DAKO Autostainer, Glostrup,
Denmark). After antigen retrieval, prediluted monoclonal
anti-Ki67 antibody (Biogenex, San Ramon, CA) was incu-
bated for 30 minutes, and antibody demonstration was
achieved using the commercially available anti-mouse IgG
detection kit (EnVision; DakoCytomation, Carpenteria, CA).
Primary antibodies were replaced with mouse immunoglob-
ulin, which served as negative controls. Growth fraction (GF)
was defined as the percentage of Ki67+ randomly chosen
nuclei per 600 tumor cells. In situ DNA fragmentation, using
the TUNEL technique, was performed on paraffin-embedded
sections with the use of the ApoTag Plus Peroxidase In Situ
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Apoptosis Detection Kit (Intergen Company, Oxford, UK), in
accordance with the manufacturer’s recommendations. The
number of apoptotic tumor cells was determined per 600 ran-
domly chosen tumor cells. Corresponding hematoxylin–eosin
sections were analyzed to avoid miscounting necrotic cells.
Statistical Analysis
All data were statistically analyzed with SPSS V.12
(SPSS, Inc., Chicago, IL) for Windows (Microsoft Corpora-
tion, Redmond, WA). Because the T393C single-nucleotide
polymorphism (SNP) shows a gene–dose effect [8], linear
analysis of variance (ANOVA) was used for the comparison
of continuous parametric variables. Relationships between
ordinal parameters were investigated using two-tailed chi-
square analysis or Fisher’s exact test (where case numbers
were low). Overall survival (OS) curves were estimated using
the Kaplan-Meier method, and differences in survival curves
were compared by the log-rank test. For multivariate analy-
sis, the Cox regression model was used. All parameters that
showed statistical significance on univariate survival analysis
were included in the Cox regression analysis. Overall, 95%
confidence intervals (95% CIs) were used throughout. Com-
patibility with the Hardy-Weinberg equilibrium was calculated
with the public domain program HWE, which was developed
by J. Ott (http:// linkage.rockefeller.edu/ott/linkutil.htm).
Results
T393C genotype distribution and the demographic character-
istics of the whole series (exploration and resection group)
are displayed in Table 1.
The mean age was 59.5 years, and the mean follow-up
was 13.8 months. The frequency of Tallele (fT) in the patient
group was 0.41, and genotype distribution was compatible
with the Hardy-Weinberg equilibrium. To investigate whether
T393C polymorphism is predictive of an increased risk for
developing ICC, we compared genotypes and allele fre-
quencies with those from 163 age-matched and sex-matched
healthywhite blood donors (CC, n = 43; TC, n = 87; TT, n = 33)
[11]. Genotype distribution and T-allele frequency (fT = 0.47)
were not significantly (P = .18) different from those of the
patient group (fT = 0.41), which argues against the associa-
tion of T393C genotypes with an increased susceptibility for
ICC. In the resection group, gender, mean age, histologic
grading, staging (T classification), lymph or blood vessel
infiltration, lymph node status, distant metastasis, multifocal
tumor growth, International Union Against Cancer (UICC)
stage, tumor size, and resection status were not associated
with genotype (Table 2).
GNAS1 T393C Genotypes and Proliferation/Apoptosis
ICC cases of the resection group were subject to analyses
of proliferation and apoptosis. Three caseswere not available
for analysis due to lack of suitable materials. There was a
significantly higher number of Ki67+ tumor cells per 600 tumor
nuclei in TT genotypes compared to grouped CC/CT geno-
types (ANOVA test, P = .008). Tumors with a TT genotype
exhibited the lowest mean value of apoptotic tumor cells.
The rate of apoptosis gradually increases from TC geno-
types to CC genotypes (Table 3).
Clinical Outcome By GNAS1 T393C Genotypes
Recurrence-free survival and tumor-specific OS depen-
dent on T393C genotypes were analyzed using Kaplan-
Meier survival curves (Figure 1). R1/R2–resected patients
exhibited a reduced tumor-specificOS,whereas patientswho
underwent explorative laparotomy without further surgical
therapy exhibited the lowest tumor-specific OS (Figure 1A).
Survival analysis of the complete series, including cases with
explorative laparotomy and curative resection, showed that
disease-specific OS was significantly dependent on T393C
genotype (P = .02), with TT genotypes showing reduced
survival compared to patients carrying at least one C allele
(Figure 1B). The level of significance increased when CC and
CT genotypes were grouped together (P < .008). Regarding
the resection group, tumor-specific OS and time to local
recurrence were again significantly dependent on T393C
genotype (Figure 2). Patients with a TT genotype displayed
a higher risk for death compared to patients with CC/CT
genotype (P = .03; Figure 2A). The unfavorable prognostic
effect of tumors with TT genotypes again increased when CC
and CT genotypes were combined for Kaplan-Meier analysis
(P < .007). The significance increased in the subgroup of
patients with primarily R0-resected ICC (P < .001; Figure 2B).
In addition, TT-homozygous patients with primarily an R0
resection status were at higher risk for local recurrence than
were heterozygous or CC-homozygous patients (P = .03;
Figure 2C). Parallel univariate survival analysis showed a
significant association of resection status (P < .001), tumor
size (P = .01), multifocal tumor growth (P = .02), higher UICC
stage (P = .04), vascular invasion (P = .06), and the presence
of lymph node metastasis (P = .05) with a reduced tumor-
specific OS. To clarify the independent prognostic value of
T393C polymorphism in patients with resected ICC, multi-
variate analysis of relevant parameters that revealed a
prognostic significance on univariate survival analysis was
performed. Cox regression analysis demonstrated R classi-
fication to be the best prognostic factor for disease-specific
OS, followed by T393C polymorphism. T393C polymor-
phism was identified as a prognostic parameter, with T393
Table 1. GNAS1 T393C Genotype Distribution and Demographic Characteristics in 87 Patients (Resection and Exploration Group) with ICC.
All (N = 87) TT (n = 15; 17.2%) TC (n = 41; 47.1%) CC (n = 31; 35.6%) P
Gender (M/F) 40/46 7/8 19/21 14/17 .88
Age (in years) at diagnosis (mean ± SD) 59.5 ± 11.2 58 ± 9.9 61.5 ± 11.1 57.6 ± 11.8 .30
P values were calculated using chi-square analysis and ANOVA for continuous variables.
GNAS1 in Intrahepatic Cholangiocarcinoma Schmitz et al. 161
Neoplasia . Vol. 9, No. 2, 2007
homozygosity being an independent prognostic marker for
reduced tumor-specific OS (hazard ratio = 2.47; 95%
CI = 1.03–7.28) (Table 4).
Discussion
Although clinicopathological parameters such as UICC
stages and resection status [3,20] may serve as prognostic
markers in ICC, markers facilitating amore precise prediction
of the clinical outcome of individual patients are still desirable.
The majority of prognostic markers are based on features of
the tumor tissue itself (e.g., expressions of proteins or genes;
somatic mutations of tumor-specific oncogenes or tumor-
suppressor genes). In this study, we examined the putative
effect of a host factor, the GNAS1 T393C polymorphism. In
contrast to conventional tumor-based prognostic markers,
SNPs can be determined independently of the availability
and/or the quality of tumor biopsy materials.
Our data demonstrate a significant association of both
disease-specific OS and recurrence-free survival with the
homozygous TT genotype of the GNAS1 gene. Patients with
T393 homozygosity exhibit a decreased survival time regard-
less of their resection status and show earlier tumor recur-
rence. Even in the group of patients exclusively undergoing
explorative laparotomy, the proportion of homozygous TT
carriers increased compared to that of healthy blood donors.
To date, only a few studies dealing with the potential
function of T393C polymorphism in the GNAS1 gene have
been published. In vitro experiments suggested that an
increased expression of Gas is associated with enhanced
apoptosis [21–23]. Activated Gas generates the second
messenger cAMP, which seems to play a major role in this
proapoptotic process [13–15]. Recent investigations by our
group showed a significant association of the C allele with an
unfavorable clinical course in bladder cancer, sporadic colo-
rectal cancer, and clear cell renal cell carcinoma [9,8,11].
Moreover, these studies yielded additional insights into
the putative functional effect of GNAS1 polymorphism: (1)
GNAS1 TT genotype was associated with increased Gas
Table 2. GNAS1 T393C Genotype Distribution, Demographic Characteristics, and Clinicopathological Characteristics in 47 Patients of the Resection Group.
All (N = 47) TT (n = 7; 14.9%) TC (n = 21; 44.7%) CC (n = 19; 40.4%) P
Gender (M/F) 4/3 11/10 5/14 .17
Age (in years) at diagnosis (mean ± SD) 58.3 ± 11.8 58.9 ± 6.6 59 ± 12.1 57.26 ± 13.4 .89
Grading [n (%)]
G1 2 (4.3) 0 (0) 0 (0) 2 (100) .49
G2 28 (59.6) 4 (14.3) 14 (50) 10 (35.7)
G3 17 (36.2) 3 (17.6) 7 (41.2) 7 (41.2)
UICC stage grouping (sixth edition)
I 9 0 (0) 5 (55.6) 4 (44.4) .21
II 3 0 (0) 3 (100) 0 (0)
III (A–C) 30 7 (23.3) 11 (36.7) 12 (40)
IV 5 0 (0) 2 (40) 3 (60)
Staging [n (%)]
T1 11 (23.4) 1 (9.1) 6 (54.5) 4 (36.4) .80
T2 7 (14.9) 2 (28.6) 3 (42.9) 2 (28.6)
T3 23 (48.9) 4 (17.4) 9 (39.1) 10 (43.5)
T4 6 (12.8) 0 (0) 3 (50) 3 (50)
Lymph vessel infiltration
L0 34 (72.3) 5 (14.7) 16 (47.1) 13 (38.2) .86
L1 13 (27.7) 2 (15.4) 5 (38.5) 6 (46.2)
Blood vessel infiltration
V0 26 (55.3) 2 (7.7) 15 (57.7) 9 (34.6) .09
V1 21 (44.7) 5 (23.8) 6 (28.6) 10 (47.6)
Nodal status
0 29 (61.7) 3 (10.3) 15 (51.7) 11 (37.9) .37
1 18 (38.3) 4 (22.2) 6 (33.3) 8 (44.4)
Distant metastasis
No 42 (89.4) 7 (16.7) 19 (45.2) 16 (38.1) .50
Yes 5 (10.6) 0 (0) 2 (40) 3 (60)
Solitary tumor 20 3 (15) 11 (55) 6 (30) .49
Multifocal tumor 26 4 (15.4) 10 (38.5) 12 (46.2)
Tumor size 8.8 8.5 ± 3.1 8.6 ± 4.0 9.3 ± 3.1 .80
Resection status
R0 26 (55.3) 3 (11.5) 13 (50) 10 (38.5) .65
R1/R2 21 (44.7) 4 (19) 8 (38.1) 9 (42.9)
P values were calculated using chi-square analysis and ANOVA for continuous variables.
Table 3. GNAS1 T393C Genotype Distribution, Apoptosis (TUNEL), and
Proliferative Activity (Ki67) in the Resection Group.
All TT TC CC P
Apoptosis (n = 46)
(% positively
stained tumor cells)
1.9 ± 2.0 1.2 ± 0.7 1.8 ± 1.8 2.3 ± 2.6 .51
GF (n = 45) (% Ki67+
tumor cell nuclei)
8.5 ± 6.3 14.1 ± 6.5 6.6 ± 5.7 8.3 ± 6.0 .02
P values were calculated using ANOVA for continuous variables.
Data are presented as mean ± SD.
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mRNA expression in a variety of human tissues, including
tumor tissues [8]; and (2) as predicted by MFOLD, T!C
substitution of the GNAS1 gene changed the mRNA folding
structures [9]. These findings tempt us to hypothesize that
genotype-dependent differences in mRNA decay due to
structural alteration may cause differences in Gas mRNA
expression. However, so far, no functional studies verifying
this hypothesis exist.
Figure 1. Kaplan-Meier survival plot for disease-specific OS in the com-
plete series on R status and exploration group (A) and on different T393C
genotypes (B).
Figure 2. Kaplan-Meier survival curves in the subgroup of resected ICC
(n = 47) (A) and in the subgroup of R0-resected tumors (n = 26) (B) in relation
to different T393C genotypes. Survival plot for local recurrence-free survival
in the subgroup of R0-resected ICC (n = 20) in relation to different T393C
genotypes (C).
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It is intriguing to note that, in contrast to our findings on
many other carcinoma types, homozygous TT carriers with
ICC were associated with the least favorable clinical course.
Nevertheless, the biologic relevance of the finding of the
present study is supported by a significantly higher prolif-
eration rate (demonstrated immunohistochemically by the
proliferation marker Ki67) in patients with homozygous TT
genotype. Our finding of elevated GF suggests an impaired
balance between cell loss and cell gain, resulting in a shift
toward tumor net growth due to increased proliferation.
However, an increased proliferation rate is the result of a
complex biologic signaling cascade, which still remains to
be elucidated.
In a very recent study on breast carcinoma, we observed
the same finding [24]. Homozygous TT carriers with breast
carcinoma exhibited the least favorable clinical course. This
finding highly suggests that the putative biologic effect of
the T393C SNP may act differently in different tumor types.
In vitro studies have demonstrated that there exist funda-
mental differences in the mechanism of Gas stimulation of
different adenylyl cyclases, which may be a possibility for the
varied responses by different cells and tissues to receptor
ligands elevating cAMP levels [25]. Besides the principal
effectors induced by cAMP, protein kinase A and protein
kinase C, novel receptors for cAMP have been recently
identified. These proteins, designated as EPAC (exchange
protein directly activated by cAMP) or RasGRP (Ras guanine
nucleotide– releasing protein), are able tomediate the effects
of cAMP in a protein kinase–independent fashion. Among
these are theB-Raf andMEK/Erk pathways, which are able to
induce cell immortalization, growth factor– independent
growth, insensitivity to growth-inhibitory signals, and avoid-
ance of apoptosis [26–28]. Future research has to elucidate
whether the various genotypes of T393Cpolymorphismof the
GNAS1 gene can be associated in a tumor type–dependent
manner with the activation of different pathways mediating
tumor progression. It would be desirable to explain the under-
lying biologic processes of the different clinical impacts of
GNAS1 genotypes; however, such functional studies were
beyond the scope of this study.
We are aware that the findings of the present study are
based on a rather small number of cases and, therefore, the
biologic significance of the results presented may be limited.
Nevertheless, we want to point out that the present cohort
of ICC is, to the best of our knowledge, one of the largest
series published. Moreover, the present study group is rather
homogenous because all cases with liver cirrhosis, regard-
less of its origin, were excluded from our study to maintain
the high homogeneity of our cohort and to rule out cirrhosis-
related influence on patient survival.
In conclusion, our data identified T393 GNAS1 homozy-
gosity as an independent prognostic parameter in ICC.
However, T393 homozygosity, which was shown to be as-
sociated with a favorable clinical outcome in sporadic colo-
rectal cancer, clear cell renal cell, carcinoma, and bladder
cancer, seems to contribute to the tumor progression of
ICC in a different manner we cannot explain yet. However,
just like in ICC, T393 homozygosity in breast carcinoma
[25] seems to be associated with an unfavorable clinical
course, thus supporting our findings. Although we could
observe elevated proliferative activity and a trend toward de-
creased apoptosis in TT-homozygous tumors, further studies
are necessary to elucidate the complex and obviously differ-
ing functional effects induced by GNAS1 polymorphism in
human carcinomas.
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